Novo Nordisk: Is The GLP‑1 Golden Age Already Behind It? (Archive)
Novo Nordisk faces eroding GLP‑1 leadership, intensifying `1qcompetition, and mounting margin headwinds.
This 5-Minute Pitch was originally published on Seeking Alpha. It is shared here to showcase my work and track record. 5-Minute Pitches published only this site will not be disseminated anywhere else and will remain behind a paywall, accessible only to Hunter Tier members.
Elevator Pitch
- Novo Nordisk is losing GLP-1 and diabetes market share in key regions as Eli Lilly's Zepbound and Mounjaro gain U.S. leadership.
- NVO's latest GLP-1 drug delivered weaker weight loss than Eli Lilly's, clouding the outlook for the company's next wave of obesity drugs.
- Competition and drug pricing regulations are driving negative margin surprises. I expect these headwinds to persist.
- Semaglutide patents are expiring in several large ex-US markets, enabling cheap generics that could cannibalize Ozempic and Wegovy over time and pressure gross margins further.
- Despite trading at a large discount to its historical and sector PEs, Novo Nordisk's weak technicals and deteriorating fundamentals argue against a near-term rebound.
Read the full article here.
